ART-0380 is under clinical development by Artios Pharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ART-0380’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ART-0380 is under development for the treatment of advanced or metastatic solid tumors including platinum-resistant metastatic ovarian cancer, primary peritoneal cancer and fallopian tube cancer. It acts by targeting ataxia telangiectasia and rad3 related protein (ATR) kinase. The drug candidate is being developed based on DNA damage response (DDR) program. It is administered through oral route.
Artios Pharma overview
Artios Pharma is a developer of therapies to treat cancer. The company carries out the development of DNA Damage Response (DDR) therapies to treat cancer. It also provides clinical trial services such as ART0380 and ART4215. The company’s product candidate ART0380 is an ataxia telangiectasia and Rad3-related protein (ATR) inhibitor used for preserving DNA integrity in healthy tissue and ART4215 is a Pol? inhibitor that is used for the treatment of cancers. The company is funded by Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments LP, Soleus Capital, Piper Heartland Healthcare Capital, CaaS Capital Management and Schroders Capital among others. Artios Pharma is headquartered in Cambridge, England, the UK.
For a complete picture of ART-0380’s drug-specific PTSR and LoA scores, buy the report here.